Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali; N. Abecassis; S. Bauer; R. Biagini; S. Bielack; S. Bonvalot; I. Boukovinas; J. V.M.G. Bovee; T. Brodowicz; J. M. Broto; A. Buonadonna; E. De Álava; A. P. Dei Tos; X. G. Del Muro; P. Dileo; M. Eriksson; A. Fedenko; V. Ferraresi; A. Ferrari; S. Ferrari; A. M. Frezza; S. Gasperoni; H. Gelderblom; T. Gil; G. Grignani; A. Gronchi; R. L. Haas; A. Hannu; B. Hassan; P. Hohenberger; R. Issels; H. Joensuu; R. L. Jones; I. Judson; P. Jutte; S. Kaal; B. Kasper; K. Kopeckova; D. A. Krákorová; A. Le Cesne; I. Lugowska; O. Merimsky; M. Montemurro; M. A. Pantaleo; R. Piana; P. Picci; S. Piperno-Neumann; A. L. Pousa; P. Reichardt; M. H. Robinson; P. Rutkowski; A. A. Safwat; P. Schöffski; S. Sleijfer; S. Stacchiotti; K. Sundby Hall; M. Unk; F. Van Coevorden; W. Van Der Graaf; J. Whelan; E. Wardelmann; O. Zaikova; J. Y. Blay

doi:10.1093/annonc/mdy096

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali, N. Abecassis, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J. V.M.G. Bovee, T. Brodowicz, J. M. Broto, A. Buonadonna, E. De Álava, A. P. Dei Tos, X. G. Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. FerrariA. M. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R. L. Haas, A. Hannu, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, R. L. Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D. A. Krákorová, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M. A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A. L. Pousa, P. Reichardt, M. H. Robinson, P. Rutkowski, A. A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Sundby Hall, M. Unk, F. Van Coevorden, W. Van Der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J. Y. Blay

Research output: Contribution to journal › Article › peer-review

545 Citations (Scopus)

Original language	English
Pages (from-to)	iv51-iv67
Journal	Annals of Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy096
Publication status	Published - 1 Oct 2018

Access to Document

10.1093/annonc/mdy096

Cite this

Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., Buonadonna, A., De Álava, E., Dei Tos, A. P., Del Muro, X. G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., ... Blay, J. Y. (2018). Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29, iv51-iv67. https://doi.org/10.1093/annonc/mdy096

@article{b6c1600d79144174bdca3aeef127d94d,

title = "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",

author = "Casali, {P. G.} and N. Abecassis and S. Bauer and R. Biagini and S. Bielack and S. Bonvalot and I. Boukovinas and Bovee, {J. V.M.G.} and T. Brodowicz and Broto, {J. M.} and A. Buonadonna and {De {\'A}lava}, E. and {Dei Tos}, {A. P.} and {Del Muro}, {X. G.} and P. Dileo and M. Eriksson and A. Fedenko and V. Ferraresi and A. Ferrari and S. Ferrari and Frezza, {A. M.} and S. Gasperoni and H. Gelderblom and T. Gil and G. Grignani and A. Gronchi and Haas, {R. L.} and A. Hannu and B. Hassan and P. Hohenberger and R. Issels and H. Joensuu and Jones, {R. L.} and I. Judson and P. Jutte and S. Kaal and B. Kasper and K. Kopeckova and Kr{\'a}korov{\'a}, {D. A.} and {Le Cesne}, A. and I. Lugowska and O. Merimsky and M. Montemurro and Pantaleo, {M. A.} and R. Piana and P. Picci and S. Piperno-Neumann and Pousa, {A. L.} and P. Reichardt and Robinson, {M. H.} and P. Rutkowski and Safwat, {A. A.} and P. Sch{\"o}ffski and S. Sleijfer and S. Stacchiotti and {Sundby Hall}, K. and M. Unk and {Van Coevorden}, F. and {Van Der Graaf}, W. and J. Whelan and E. Wardelmann and O. Zaikova and Blay, {J. Y.}",

note = "Funding Information: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker{\textquoteright}s honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Domp{\'e}, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has received Eli Lilly, Epizyme, Genzyme, Ipsen, Loxo Oncology, Medspace, research funds from Bristol-Myers Squibb, Merck Sharp & Nektar, Novartis, Philogen, Piqur Therapeutics, Plexxikon, is a Dohme, Novartis, Roche, Amgen and has reported advisory roles member of speaker{\textquoteright}s bureau of Bayer, Eisai, Eli Lilly, for AstraZeneca, Roche, Merck Sharp & Dohme, LEO Pharma, GlaxoSmithKline, Novartis, PharmaMar, Swedish Orphan Amgen, Bristol-Myers Squibb, Pfizer and Novartis; TB has Biovitrium, has received research grants from Bayer, Blueprint reported honoraria from Roche and PharmaMar and advisory Medicines, CoBioRes, Exelixis, Bristol-Myers Squibb, Novartis, board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Plexxikon, and has received travel grants from Sixth Element Lilly; JMB has reported consulting advisory role for PharmaMar, Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Lilly, Bayer, Novartis and being a member of the speaker{\textquoteright}s bureau Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Cristal for PharmaMar and received travel grants from PharmaMar and Therapeutics, Daichii Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Lilly; APDT is a member of the speakers{\textquoteright} bureau for Lilly, Pfizer Genzyme, GlaxoSmithKline, Ipsen, Loxo Oncology, Medpace, and Merck Sharp & Dohme; XGDM has reported advisory role Nektar, Novartis, PharmaMar, Philogen, Piqur Therapeutics, for Lilly, PharmaMar and Novartis; PD has reported conducted Plexxikon, Swedish Orphan Biovitrium; SSt has received honora-research sponsored by Eli Lilly; ME has participated in advisory ria from Eli Lilly and PharmaMar, research grants from Amgen boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has con-Domp{\'e}, Advenchen, Bayer, Eli Lilly, Daiichi Sankyo Pharma, ducted studies sponsored by Amgen Domp{\'e}, AROG Bayer, Epizyme Inc., Novartis, Pfizer and PharmarMar; travel grants Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, from PharmaMar and has reported advisory/consultant roles for GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar; research grants and honoraria from Novartis, Pfizer and Bayer; WVdG has received research grants from Novartis; EW has HG has received research grants from Novartis, Daiichi Sankyo reported travel/research grants and/or honoraria from Novartis Pharma and Pfizer; AG has reported compensation for advisory Oncology, Milestone, Menarini, PharmaMar, Roche, Nanobiotix boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and and Bayer; JYB has declared research grants and honoraria from Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Novartis, GlaxoSmithKline, Pfizer and Bayer; IL has received Nanobiotix, and research funds from PharmaMar and travel honoraria from Bristol-Myers Squibb, MDS, Roche, Novartis grants from PhramaMar and Nanobiotix; BH has received and Pfizer for scientific presentations or research; NA, RB, research grants from EuroSarc and has conducted research with JVMGB, AB, EDA, AFed, VF, AFer, GG, TG, RLH, RI, SK, DAK, EIT Health in collaboration with GE healthcare and Philips, he RP, PP, SP-N, ALP, OM, MM, MHR, AAS, SSl, KSH, MU, JW has received reagents from Takeda and Astellas to conduct clini-and FVC have declared no conflict of interest. SF, AH and OZ cal trials without direct funding; PH has reported conducting have not reported any potential conflicts of interest. research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co- appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Novartis, Pfizer and Bayer and advisory role for Bayer; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; Pfizer and Bayer; IL has received honoraria from Bristol-Myers Squibb, MDS, Roche, Novartis and Pfizer for sci- entific presentations or research; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and Lilly and has received honoraria from Novartis, Pfizer, Bayer, PharmaMar and Lilly; PRu has received honoraria for lectures from Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and has served as a member of advisory board for Novartis, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Blueprint Medicines; PS has received honoraria from Daiichi Sankyo Pharma, Eisai, Eli Lilly, Medspace, Novartis and Swedish Orphan Biovitrium, has reported consulting or advising roles for Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boeringer Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai,",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy096",

language = "English",

volume = "29",

pages = "iv51--iv67",

journal = "Annals of Oncology",

issn = "0923-7534",

}

Casali, PG, Abecassis, N, Bauer, S, Biagini, R, Bielack, S, Bonvalot, S, Boukovinas, I, Bovee, JVMG, Brodowicz, T, Broto, JM, Buonadonna, A, De Álava, E, Dei Tos, AP, Del Muro, XG, Dileo, P, Eriksson, M, Fedenko, A, Ferraresi, V, Ferrari, A, Ferrari, S, Frezza, AM, Gasperoni, S, Gelderblom, H, Gil, T, Grignani, G, Gronchi, A, Haas, RL, Hannu, A, Hassan, B, Hohenberger, P, Issels, R, Joensuu, H, Jones, RL, Judson, I, Jutte, P, Kaal, S, Kasper, B, Kopeckova, K, Krákorová, DA, Le Cesne, A, Lugowska, I, Merimsky, O, Montemurro, M, Pantaleo, MA, Piana, R, Picci, P, Piperno-Neumann, S, Pousa, AL, Reichardt, P, Robinson, MH, Rutkowski, P, Safwat, AA, Schöffski, P, Sleijfer, S, Stacchiotti, S, Sundby Hall, K, Unk, M, Van Coevorden, F, Van Der Graaf, W, Whelan, J, Wardelmann, E, Zaikova, O & Blay, JY 2018, 'Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up', Annals of Oncology, vol. 29, pp. iv51-iv67. https://doi.org/10.1093/annonc/mdy096

TY - JOUR

T1 - Soft tissue and visceral sarcomas

T2 - ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - Casali, P. G.

AU - Abecassis, N.

AU - Bauer, S.

AU - Biagini, R.

AU - Bielack, S.

AU - Bonvalot, S.

AU - Boukovinas, I.

AU - Bovee, J. V.M.G.

AU - Brodowicz, T.

AU - Broto, J. M.

AU - Buonadonna, A.

AU - De Álava, E.

AU - Dei Tos, A. P.

AU - Del Muro, X. G.

AU - Dileo, P.

AU - Eriksson, M.

AU - Fedenko, A.

AU - Ferraresi, V.

AU - Ferrari, A.

AU - Ferrari, S.

AU - Frezza, A. M.

AU - Gasperoni, S.

AU - Gelderblom, H.

AU - Gil, T.

AU - Grignani, G.

AU - Gronchi, A.

AU - Haas, R. L.

AU - Hannu, A.

AU - Hassan, B.

AU - Hohenberger, P.

AU - Issels, R.

AU - Joensuu, H.

AU - Jones, R. L.

AU - Judson, I.

AU - Jutte, P.

AU - Kaal, S.

AU - Kasper, B.

AU - Kopeckova, K.

AU - Krákorová, D. A.

AU - Le Cesne, A.

AU - Lugowska, I.

AU - Merimsky, O.

AU - Montemurro, M.

AU - Pantaleo, M. A.

AU - Piana, R.

AU - Picci, P.

AU - Piperno-Neumann, S.

AU - Pousa, A. L.

AU - Reichardt, P.

AU - Robinson, M. H.

AU - Rutkowski, P.

AU - Safwat, A. A.

AU - Schöffski, P.

AU - Sleijfer, S.

AU - Stacchiotti, S.

AU - Sundby Hall, K.

AU - Unk, M.

AU - Van Coevorden, F.

AU - Van Der Graaf, W.

AU - Whelan, J.

AU - Wardelmann, E.

AU - Zaikova, O.

AU - Blay, J. Y.

N1 - Funding Information: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker’s honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Dompé, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has received Eli Lilly, Epizyme, Genzyme, Ipsen, Loxo Oncology, Medspace, research funds from Bristol-Myers Squibb, Merck Sharp & Nektar, Novartis, Philogen, Piqur Therapeutics, Plexxikon, is a Dohme, Novartis, Roche, Amgen and has reported advisory roles member of speaker’s bureau of Bayer, Eisai, Eli Lilly, for AstraZeneca, Roche, Merck Sharp & Dohme, LEO Pharma, GlaxoSmithKline, Novartis, PharmaMar, Swedish Orphan Amgen, Bristol-Myers Squibb, Pfizer and Novartis; TB has Biovitrium, has received research grants from Bayer, Blueprint reported honoraria from Roche and PharmaMar and advisory Medicines, CoBioRes, Exelixis, Bristol-Myers Squibb, Novartis, board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Plexxikon, and has received travel grants from Sixth Element Lilly; JMB has reported consulting advisory role for PharmaMar, Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Lilly, Bayer, Novartis and being a member of the speaker’s bureau Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Cristal for PharmaMar and received travel grants from PharmaMar and Therapeutics, Daichii Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Lilly; APDT is a member of the speakers’ bureau for Lilly, Pfizer Genzyme, GlaxoSmithKline, Ipsen, Loxo Oncology, Medpace, and Merck Sharp & Dohme; XGDM has reported advisory role Nektar, Novartis, PharmaMar, Philogen, Piqur Therapeutics, for Lilly, PharmaMar and Novartis; PD has reported conducted Plexxikon, Swedish Orphan Biovitrium; SSt has received honora-research sponsored by Eli Lilly; ME has participated in advisory ria from Eli Lilly and PharmaMar, research grants from Amgen boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has con-Dompé, Advenchen, Bayer, Eli Lilly, Daiichi Sankyo Pharma, ducted studies sponsored by Amgen Dompé, AROG Bayer, Epizyme Inc., Novartis, Pfizer and PharmarMar; travel grants Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, from PharmaMar and has reported advisory/consultant roles for GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar; research grants and honoraria from Novartis, Pfizer and Bayer; WVdG has received research grants from Novartis; EW has HG has received research grants from Novartis, Daiichi Sankyo reported travel/research grants and/or honoraria from Novartis Pharma and Pfizer; AG has reported compensation for advisory Oncology, Milestone, Menarini, PharmaMar, Roche, Nanobiotix boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and and Bayer; JYB has declared research grants and honoraria from Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Novartis, GlaxoSmithKline, Pfizer and Bayer; IL has received Nanobiotix, and research funds from PharmaMar and travel honoraria from Bristol-Myers Squibb, MDS, Roche, Novartis grants from PhramaMar and Nanobiotix; BH has received and Pfizer for scientific presentations or research; NA, RB, research grants from EuroSarc and has conducted research with JVMGB, AB, EDA, AFed, VF, AFer, GG, TG, RLH, RI, SK, DAK, EIT Health in collaboration with GE healthcare and Philips, he RP, PP, SP-N, ALP, OM, MM, MHR, AAS, SSl, KSH, MU, JW has received reagents from Takeda and Astellas to conduct clini-and FVC have declared no conflict of interest. SF, AH and OZ cal trials without direct funding; PH has reported conducting have not reported any potential conflicts of interest. research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co- appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Novartis, Pfizer and Bayer and advisory role for Bayer; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; Pfizer and Bayer; IL has received honoraria from Bristol-Myers Squibb, MDS, Roche, Novartis and Pfizer for sci- entific presentations or research; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and Lilly and has received honoraria from Novartis, Pfizer, Bayer, PharmaMar and Lilly; PRu has received honoraria for lectures from Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and has served as a member of advisory board for Novartis, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Blueprint Medicines; PS has received honoraria from Daiichi Sankyo Pharma, Eisai, Eli Lilly, Medspace, Novartis and Swedish Orphan Biovitrium, has reported consulting or advising roles for Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boeringer Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai,

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85052604766&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy096

DO - 10.1093/annonc/mdy096

M3 - Article

C2 - 29846498

AN - SCOPUS:85052604766

SN - 0923-7534

VL - 29

SP - iv51-iv67

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Access to Document

Other files and links

Cite this